| (19) |
 |
|
(11) |
EP 0 494 405 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
28.10.1992 Bulletin 1992/44 |
| (43) |
Date of publication A2: |
|
15.07.1992 Bulletin 1992/29 |
| (22) |
Date of filing: 01.01.1992 |
|
| (51) |
International Patent Classification (IPC)5: A61K 31/425 |
|
| (84) |
Designated Contracting States: |
|
AT BE CH DE DK ES FR GB GR IT LI LU MC NL PT SE |
| (30) |
Priority: |
10.01.1991 US 639275
|
| (60) |
Divisional application: |
|
96200042.8 / 0715853 |
| (71) |
Applicant: Transcend Therapeutics, Inc. |
|
Cambridge
Massachusetts 02139 (US) |
|
| (72) |
Inventor: |
|
- Goldberg, Dennis
Palatine, Illinois 60067 (US)
|
| (74) |
Representative: MacGregor, Gordon et al |
|
ERIC POTTER CLARKSON
St. Mary's Court
St. Mary's Gate
Nottingham, NG1 1LE
Nottingham, NG1 1LE (GB) |
|
| |
|
| (54) |
Use of thiazolidine-4-carboxylate derivatives for the treatment of pulmonary diseases |
(57) The present invention provides for the preparation of a composition used for treating
pulmonary disease. More specifically, the present invention provides for the preparation
of a composition for treating diseases such as adult respiratory distress syndrome
which result in oxidative stress that damages the cells of the lung. Pursuant to present
invention, a non-cysteine substrate that is a precursor for the intracellular synthesis
of glutathione is used to create a composition that is administered to a patient and
increases the intracellular glutathione levels of at least the cells of the lungs
of a patient with pulmonary disease.